Quarterly Conference Calls, In Brief

Bristol earnings restatement: Bristol-Myers Squibb expects to "reallocate" approximately $2 bil. in sales recorded during 2000 and 2001 in its upcoming 10-Q filing with the Securities & Exchange Commission. "The expected restatement is based on further review and consideration of the company's accounting for its previously disclosed wholesaler inventory situation and on recent advice from the company's auditors, PricewaterhouseCoopers LLP, based on their ongoing assessment of the company's sales practices in the U.S. pharmaceuticals business and related accounting," Bristol says. The company's accounting for wholesaler inventories is under investigation by the SEC and Department of Justice (1"The Pink Sheet" Oct. 14, In Brief)....One way to boost earnings: Bristol earnings restatement will result in increases in reported revenues and earnings in 2002 (and decreases in 2000 and 2001)...